In the News

//In the News
In the News 2016-11-17T12:28:21+00:00

ViaCyte Receives $10M in Financing and ‘Go-ahead’ for Clinical Trials with PEC-Direct

With $10 million raised in financing and the ‘go-ahead’ from both the U.S. Food and Drug Administration (FDA) and Health Canada, ViaCyte is ready to begin human clinical trials of the PEC-Direct product candidate. The [...]

ViaCyte Establishes Collaborative Research Agreement with Gore

As the first company to advance a cell replacement therapy for type 1 diabetes into the clinic, ViaCyte is committed to developing a functional cure for all type 1 diabetes patients.  As part of the [...]

ViaCyte Featured in PharmaVOICE’s Innovator’s Corner

PharmaVOICE talked with Dr. Paul Laikind, ViaCyte’s President and CEO, about how the company is developing a unique stem cell-derived therapy for type 1 diabetes.  Type 1 diabetes affects an estimated 1.25 million people in [...]

ViaCyte Acquires Rights to BetaLogics Assets

For more than a decade, ViaCyte and BetaLogics have been independently working toward a stem cell-derived therapy for diabetes.  In February of 2016, ViaCyte and Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of [...]

ViaCyte Reports Promising Preliminary Results

ViaCyte reported positive preliminary results from the Company’s Phase 1/2 clinical trial of PEC-EnCap (also known as VC-01) product candidate.  The company is the first to advance an encapsulated islet cell replacement therapy for type [...]

Filmmaker Documents ViaCyte’s Quest to Find a Better Treatment for Type 1 Diabetes

Lisa Hepner, a filmmaker living with type 1 diabetes, and her husband Guy Mossman are producing a feature-length documentary on ViaCyte’s efforts to develop a better treatment for diabetes. The documentary, called The Human Trial, [...]

Diabetes Forecast: 12 Products in the Diabetes Pipeline

Diabetes Forecast highlighted ViaCyte’s first-of-a-kind islet cell replacement therapy in an article discussing twelve innovative products being developed to treat and manage type 1 diabetes. ViaCyte has discovered how to turn human stem cells into [...]

MIT Technology Review: A Pancreas in a Capsule

The MIT Technology Review published a piece expressing optimism about our “cells in a sack” approach to treating type 1 diabetes.  ViaCyte is mentioned as only the third company in the United States to test [...]

The Pharmaceutical Journal: Making Beta Cells in the Lab

The Pharmaceutical Journal interviewed Kevin D’Amour, ViaCyte’s chief scientific officer, in an article that describes several current approaches to producing beta cells as a treatment for type 1 diabetes. The piece describes our 2008 study [...]

San Diego Reader: Type 1 terror

An in-depth article in the San Diego Reader details the difficulties faced by families with a child who has type 1 diabetes — pricking fingers to test blood sugar levels every three hours, injecting insulin, [...]

MedTech Strategist: The Bioartificial Pancreas

In an in-depth piece on efforts to create an artificial pancreas for the treatment of type 1 diabetes, The MedTech Strategist interviews ViaCyte CEO Paul Laikind, Ph.D., and Michael Scott, Ph.D., ViaCyte chief development officer [...]

BioPharma Reporter: ViaCyte Wins US Patent to Manufacture Human Pancreatic Progenitor Cells

In November 2014, reported that ViaCyte won a U.S. patent to manufacture human pancreatic progenitor cells from endoderm (embryonic stem) cells.  Under this patent, we are also able to develop new ways to produce [...]

CBS 8 News: JDRF Walk – Taking Steps to Cure Type 1 Diabetes

CBS 8 News in San Diego featured a local walk to raise money for JDRF.  The piece mentioned that some of the funds would support ViaCyte and our efforts to develop and test the VC-01™ [...]

A First: ViaCyte’s Type 1 Diabetes Treatments Moves into Humans

In late October 2014, ViaCyte implanted the first VC-01 product candidate in a human patient with type 1 diabetes.  As ViaCyte CEO Paul Laikind, Ph.D., put it: “To our knowledge, this is the first time [...]

DiabetesCare: Creating a Unique Environment and Transformative Cell Supply to Re-Ignite Insulin Production interviewed ViaCyte CEO Paul Laikind, Ph.D.  In the piece, Laikind explains that one advantage of using ViaCyte’s PEC-01™ pancreatic precursor cells to treat type 1 diabetes is that, based on animal experimentation, they can [...]

U-T San Diego: Stem Cell Treatments Surging into Clinic

U-T San Diego Science reporter Bradley Fikes reported from the 2014 Stem Cell Meeting on the Mesa, an annual gathering of stem cell researchers, businesses and investors in San Diego.  He covered a talk given [...]

Knoepfler Blog: FDA Nod For ViaCyte IND of Diabetes Stem Cell-Based Product

Writing on his popular blog, stem cell researcher Paul Knoepfler, Ph.D., associate professor at UC Davis School of Medicine, shares his excitement that ViaCyte’s investigational new drug (IND) application was accepted by the FDA in [...]

U-T San Diego: In Search of a ‘Virtual Cure’ for Diabetes

Local newspaper U-T San Diego covered the news that the FDA accepted ViaCyte’s application to begin clinical trials to evaluate the VC-01™ product candidate.  The therapy will be tested for safety and efficacy in patients [...]

Popular Science: Scientists Outsmart the Immune System to Better Match People with Organs

ViaCyte’s stem cell replacement therapy for the treatment of type 1 diabetes was highlighted in a June 2012 Popular Science article on artificial organs.  The ViaCyte device, known as the Encaptra® drug delivery system, holds [...]